The FDA has approved the first over-the-counter fixed-dose combination of acetaminophen and naproxen sodium in a single tablet, creating a new non-opioid option for managing dental pain including toothache. For Canadian dental practices, the approval signals a broader shift toward multimodal pain management that could influence how practitioners counsel patients on post-procedural care.
As of August 2026, the post-operative pain conversation in dentistry is changing. On July 24, the U.S. Food and Drug Administration approved Tylenol with Naproxen — the first nonprescription product to combine acetaminophen and naproxen sodium into a single pill — for temporary relief of minor aches and pains including toothache. While this is a U.S. regulatory action, the clinical rationale behind it is directly relevant to Canadian dental professionals who already recommend both analgesics individually.
What the FDA Actually Approved
The approved product contains 325 mg of acetaminophen and 110 mg of naproxen sodium per tablet. A single dose consists of two tablets (totalling 650 mg acetaminophen and 220 mg naproxen sodium), taken every 12 hours. The manufacturer, Kenvue, reports that eight clinical studies demonstrated superior pain relief compared to either ingredient taken alone, with onset within 30 minutes and duration up to 12 hours.
The indication covers temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual cramps, and minor pain of arthritis in adults and children 12 years and older. The FDA granted Kenvue a three-year exclusivity period for this specific formulation.
Why This Matters for Dental Pain Management
Dental professionals in Canada and worldwide have long recommended the combination of acetaminophen and ibuprofen (or naproxen) as a first-line alternative to opioids for managing post-procedural dental pain. Multiple systematic reviews, including a frequently cited Cochrane analysis, have found that combining an analgesic with an NSAID provides pain relief comparable to or better than low-dose opioid combinations, with fewer side effects.
The significance of the FDA approval is not the combination itself — dentists have been recommending patients take both separately for years — but rather the regulatory validation of the fixed-dose form. A single pill simplifies dosing compliance. Patients are less likely to double up on one ingredient while forgetting the other, and the 12-hour dosing interval reduces the total number of pills taken per day.
Pro Tip: The acetaminophen-NSAID combination is already considered best practice for post-extraction and post-implant pain management. If you are not routinely recommending this approach over opioid prescriptions, the evidence strongly supports making the switch. The Royal College of Dental Surgeons of Ontario (RCDSO) has issued guidance encouraging non-opioid pain management protocols whenever clinically appropriate.
Canadian Availability and Regulatory Context
This specific fixed-dose product is approved for the U.S. market. Health Canada operates independently from the FDA, and there is no indication that an equivalent product has been submitted for Canadian approval at this time. Canadian dental professionals should not assume the combination tablet will be available at Canadian pharmacies in the near term.
That said, both acetaminophen and naproxen sodium are individually available over the counter in Canada, and Canadian dentists can continue to recommend the combination by instructing patients to take both separately. The clinical benefit is identical — the convenience of a single tablet is the only practical difference.
Pro Tip: When counselling patients on post-procedural pain management, provide specific written instructions rather than verbal advice alone. Include the exact dose of each medication, the timing interval, and the maximum daily dose. Written take-home instructions reduce dosing errors and improve patient satisfaction with pain control.
The Broader Opioid Reduction Context
Canada continues to face a severe opioid crisis. According to the Public Health Agency of Canada, opioid-related deaths remain at historically elevated levels across every province. Dentistry has come under increasing scrutiny for its historical role in introducing patients to prescription opioids, particularly after wisdom tooth extractions.
The Canadian Dental Association (CDA) has endorsed multimodal pain management strategies that prioritize non-opioid analgesics as first-line therapy. Ontario's opioid prescribing guidelines, reinforced by the RCDSO, explicitly recommend that dentists exhaust non-opioid options before prescribing opioids for acute dental pain. The FDA's approval of a fixed-dose non-opioid combination reinforces the clinical and regulatory momentum behind this approach.
For dental practices in the Greater Toronto Area and across Ontario, this translates to a clear practice standard: opioid prescriptions after routine extractions, endodontic procedures, or implant placements should be the exception, not the default. Practices that have already adopted non-opioid protocols are aligned with current best evidence. Those that have not should revisit their prescribing patterns.
What Practices Should Watch For
Several developments could follow this approval in the coming months:
- Canadian regulatory filing: Kenvue or another manufacturer may seek Health Canada approval for the fixed-dose combination. If approved, it would simplify patient instructions for Canadian dental offices.
- Insurance and coverage implications: OTC products are not covered by most dental benefit plans. However, if a prescription version becomes available in Canada, it could be eligible for coverage under extended health benefits.
- Updated clinical guidelines: The CDA and RCDSO may update their pain management recommendations to reference fixed-dose combination products as they become available. Provincial dental associations typically follow international evidence with a reasonable lag.
- Patient expectations: Patients who travel or read U.S. health media may ask about the product before it is available in Canada. Practices should be prepared to explain that the same ingredients are available individually and that the clinical effect is equivalent.
Safety Considerations Dental Professionals Should Communicate
While the acetaminophen-naproxen combination has a well-established safety profile, dental professionals should remind patients of key precautions:
- Acetaminophen can cause liver damage at doses exceeding 4,000 mg per day. Patients must account for acetaminophen in other products they may be taking simultaneously (cold remedies, sleep aids).
- Naproxen, as an NSAID, carries risks of gastrointestinal bleeding, particularly in older patients or those on blood thinners. This is especially relevant for patients on anticoagulant therapy, which is common in the aging population many Ontario practices serve.
- Neither analgesic addresses the underlying cause of dental pain. Patients should understand that medication manages symptoms while the dental treatment resolves the problem.
Pro Tip: Create a standardized post-procedural pain management handout for your practice that includes dosing instructions for both OTC analgesics and clear criteria for when patients should call the office (uncontrolled pain after 72 hours, fever, swelling). This reduces after-hours calls and improves patient confidence in their recovery plan.
Frequently Asked Questions
Q: Can Canadian dentists prescribe the new Tylenol with Naproxen combination pill?
Not at this time. The product is currently FDA-approved for the U.S. market only. Canadian dental professionals can recommend that patients take acetaminophen and naproxen sodium separately, which provides the same clinical benefit. Both medications are available over the counter in Canada without a prescription.
Q: Is the acetaminophen-naproxen combination more effective than opioids for dental pain?
Multiple clinical studies and systematic reviews have found that the combination of acetaminophen and an NSAID provides pain relief comparable to or better than low-dose opioid combinations for most dental procedures, with significantly fewer side effects including no risk of dependence. The RCDSO and CDA both recommend non-opioid analgesics as first-line therapy for acute dental pain.
Q: What post-operative dental pain management protocol does the RCDSO recommend?
The Royal College of Dental Surgeons of Ontario recommends that dentists use multimodal non-opioid analgesic strategies as first-line treatment for acute dental pain, reserving opioid prescriptions for cases where non-opioid alternatives have been tried and proven insufficient. This aligns with national guidelines from the Canadian Dental Association and broader Canadian opioid prescribing standards.